文献速递骨质疏松与钙磷/甲状旁腺垂体与肾上腺疾病

结节病患者的原发性甲状旁腺功能亢进症患病率与结局:大规模回顾性队列研究

Prevalence and Outcomes of Primary Hyperparathyroidism in Sarcoidosis Patients: A Large-Scale Retrospective Cohort Study.
PubMed 文献 · J Clin Endocrinol Metab · 2026-07-28

本研究基于美国TriNetX协作网络117,395例结节病成人数据,发现31.3%存在高钙血症但仅30.5%接受iPTH评估,生化定义的原发性甲状旁腺功能亢进症(PHPT)患病率为3.0%且75.4%无对应ICD-10编码,接受甲状旁腺切除术者3年全因死亡率风险显著降低(HR 4.2,95%CI 2.7-6.4)。

要点

  • 结节病患者高钙血症常见但iPTH评估率低,需警惕PHPT共存。
  • 生化定义PHPT中75.4%无ICD-10编码,提示严重诊断不足。
  • 甲状旁腺切除术与3年全因死亡率风险降低相关(HR 4.2)。

核心结论

  • 结节病患者中PHPT患病率高、评估严重不足且治疗不充分。
  • 常规iPTH检测和及时手术转诊至关重要。

研究设计与样本

  • 回顾性队列研究,基于TriNetX美国协作网络联邦电子健康记录数据。
  • 纳入117,395例有ICD-10结节病(D86)且至少一次血清钙测量的成人。

主要发现

  • 高钙血症占31.3%(n=36,790),仅30.5%接受iPTH评估。
  • 生化PHPT占3.0%(n=3,493),其中75.4%(n=2,633)无ICD-10编码。
  • 编码PHPT中甲状旁腺切除术占36.6%(n=315),生化治愈率74.6%。
  • 高钙血症全因死亡HR 1.33(95%CI 1.29-1.38),编码PHPT HR 1.50(95%CI 1.40-1.60),未手术HR 4.2(95%CI 2.7-6.4),均p<0.001。

临床怎么用

  • 对结节病患者应常规检测iPTH以识别共存PHPT。
  • 确诊PHPT后及时评估手术指征并转诊甲状旁腺切除术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PRÉCIS: Among 117,395 U.S. adults with sarcoidosis, primary hyperparathyroidism was markedly underdiagnosed: 75.4% of biochemically defined cases carried no corresponding ICD-10 code, and parathyroidectomy was associated with a 4.2-fold reduction in 3-year mortality. CONTEXT: Hypercalcemia in sarcoidosis is classically attributed to granuloma-mediated calcitriol excess, but primary hyperparathyroidism (PHPT)-the most common cause of ambulatory hypercalcemia-frequently coexists. These two etiologies are mechanistically distinct: sarcoid hypercalcemia is suppressed-PTH and 1,25(OH)2D-driven, while PHPT is autonomous-PTH-driven and surgically curable. Because both can independently sustain hypercalcemia, attribution to sarcoidosis alone risks anchoring bias and delayed identification of PHPT. OBJECTIVE: To determine PHPT prevalence in sarcoidosis, characterize hypercalcemia-evaluation adequacy, and assess parathyroidectomy (PTX) impact on all-cause mortality. DESIGN: Retrospective cohort study. SETTING: TriNetX U.S. Collaborative Network, federated EHR data from >120 million patients. PATIENTS: 117,395 adults with ICD-10 sarcoidosis (D86) and ≥1 serum calcium measurement. INTERVENTIONS: None (observational). MAIN OUTCOME MEASURES: iPTH assessment rate; biochemical and coded PHPT prevalence; PTX utilization and outcomes; all-cause mortality. RESULTS: Hypercalcemia: 31.3% (n=36,790); only 30.5% received iPTH. Biochemical PHPT: 3.0% (n=3,493)-of whom 75.4% (n=2,633) had no ICD-10 code. PTX in coded PHPT: 36.6% (n=315), with 74.6% biochemical cure. Hypercalcemia HR 1.33 (1.29-1.38), coded PHPT HR 1.50 (1.40-1.60), no-PTX HR 4.2 (2.7-6.4); all p<0.001. CONCLUSIONS: PHPT is prevalent, profoundly under-evaluated, and undertreated in sarcoidosis. Routine iPTH measurement and timely surgical referral are essential.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ghaleb A, Abdelmaksoud A, Bashumeel Y, et al. Prevalence and Outcomes of Primary Hyperparathyroidism in Sarcoidosis Patients: A Large-Scale Retrospective Cohort Study. J Clin Endocrinol Metab. 2026. PMID: 42508809. doi:10.1210/clinem/dgag302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。